Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilparencel - inRegen

Next Previous
X
Search
Drug Profile

Rilparencel - inRegen

Alternative Names: Autologous cultured kidney tissue cells - inRegen; Autologous cultured kidney tissue cells - Tengion; Autologous Neo-Kidney augment; Neo-Kidney Augment; Neo-kidney-augment; NKA; ReACT; REACT™; Regenerative autologous cell therapy; Renal Autologous Cell Therapy

Latest Information Update: 05 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tengion
  • Developer inRegen; ProKidney
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Kidney disorders; Type 2 diabetes mellitus
  • No development reported Renal failure

Most Recent Events

  • 03 Sep 2024 ProKidney terminates a phase III PROACT 2 trial in Renal failure and Type II diabetes mellitus in Austria, Spain and Portugal as trial is not required for initial USA registration (NCT05286853)
  • 13 Jun 2024 Prokidney initiates enrolment in the phase III trial for Kidney disorders (In adults, In the elderly) in Australia, Canada, Taiwan, United Kingdom and the USA (NCT05099770)
  • 10 Jun 2024 Efficacy and adverse event data from a phase II REGEN-007 trial in Kidney disorders released by ProKidney

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top